South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market size is expected to reach US$ 586.7 Million by 2031 from US$ 158.4 Million in 2024. The market is estimated to record a CAGR of 20.6% from 2025 to 2031.

Executive Summary and South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis:

The cell and gene therapy contract development and manufacturing organization market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. Governments across countries are actively supporting biopharmaceutical innovation through regulatory reforms and investments in biotech infrastructure. This governmental support has improved the investment climate and encouraged partnerships between local CDMOs and global biotech firms. Another critical driver is the increasing prevalence of genetic and rare diseases in the region, which is creating urgent demand for advanced therapies. With limited local capacity for highly specialized treatments, outsourcing to CDMOs enables efficient development and delivery of cell and gene therapies tailored to regional health needs. Additionally, advancements in healthcare infrastructure, collaboration between companies and local partners, and the growth of skilled scientific talent across South & Central America are reinforcing the region's capacity to support complex cell and gene therapy processes, including vector manufacturing, cell modification, and clinical trial support.

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market: Strategic Insights

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation Analysis:

• By Service Type, the South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Drug Development and Manufacturing, Testing and Regulatory Services, and Others. Drug Development and Manufacturing held the largest share of the market in 2024.
• By Product Type, the South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Gene Therapy and Cell Therapy. Gene Therapy held the largest share of the market in 2024.
• By End User, the South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Others. Biopharmaceutical Companies held the largest share of the market in 2024.

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Outlook

The demand for cell and gene therapies is driving biopharmaceutical companies toward CDMOs that can provide cutting-edge facilities and technologies, which are required to scale up production while ensuring quality, compliance, and regulatory approval. These specialized capabilities are essential for the production of complex and personalized therapies, which require advanced infrastructure to maintain high manufacturing standards. Cell and gene therapies, including gene editing, viral vector production, and personalized medicine, require specialized facilities equipped with the latest technologies. The production of viral vectors used in gene therapies requires GMP standard facilities to ensure the safety, consistency, and quality of the final product. These facilities should be equipped to handle complex biological materials, such as live cells and genetically modified organisms, in controlled and monitored environments. The increasing adoption of automated cell culture systems, continuous manufacturing, and digital quality monitoring systems enhances the growth and efficiency of gene therapy production. The need for specialized facilities creates a substantial opportunity for CDMOs. It is cost-effective and efficient for biopharma companies to collaborate with CDMOs that have the required technology and facilities. For instance, in 2023, Bristol-Myers Squibb collaborated with a CDMO for the production of its CAR-T cell therapy, Breyanzi. This therapy involves harvesting, modifying, and expanding a patient's T-cells, a process requiring specialized technology and facilities to ensure the desired therapeutic effect. By leveraging CDMO expertise in specialized facilities, Bristol-Myers Squibb was able to scale production while ensuring regulatory compliance and quality. Thus, the soaring need for advanced manufacturing capabilities with advanced technology is expected to create future growth opportunities for the cell and gene therapy contract research and development organization market.

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Country Insights

By country, the South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2024.

The country's government has played a pivotal role in fostering the cell and gene therapy sector. According to a report titled "First Gene Therapy Products Approved in Brazil," published by Law Business Research 2020, Brazil is the first among the Latin American countries to approve the marketing of gene therapy products. Specifically, the Brazilian Health Regulatory Agency (ANVISA) granted marketing authorization for Novartis' gene therapy products, Luxturna and Zolgensma. Both products have been approved by the Brazilian Technical Commission of Biosafety (CTNBio). This initiative has facilitated the entry of innovative treatments into the market and attracted international CDMOs to establish operations in Brazil.

The demand for cell and gene therapies is further bolstered by Brazil's large patient population and the prevalence of genetic disorders. As per a study titled "Medical genetics workforce in Brazil: practitioners, services, and disease distribution," published in 2021, ~53,746 live births were with rare genetic diseases. Similarly, as per a study titled "The Brazilian Rare Genomes Project," published in May 2022, 13.2 million individuals were affected by rare diseases in Brazil. This creates a substantial demand for innovative therapies in the country and supports the growth of CDMOs.

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Company Profiles

Some of the key players operating in the market include Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Pluri Inc, Aenova Holding GmbH, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, Thermo Fisher Scientific Inc., Minaris Advanced Therapies, and SK pharmteco Inc.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise